When to Check AMH: Timing Recommendations
AMH should be measured in the early follicular phase (day 2-5) of the menstrual cycle, and ideally measured in the same cycle as any planned controlled ovarian stimulation (COS) to maximize predictive accuracy for ovarian response.
Optimal Timing for AMH Measurement
Early Follicular Phase is Standard
AMH measurement is traditionally performed in the early follicular phase of the menstrual cycle, though the evidence shows AMH exhibits cycle-to-cycle and intra-cycle variability that has important clinical implications 1, 2, 3.
Critical Finding: Measure in the COS Cycle Itself
The most recent and highest-quality evidence demonstrates that AMH measured in the actual COS cycle shows significantly stronger correlation with outcomes compared to measurements from preceding cycles 1:
- COS cycle AMH correlated with total oocyte count (r = 0.871, P < 0.001)
- COS cycle AMH correlated with mature oocyte count (r = 0.820, P < 0.001)
- These correlations were substantially stronger than AMH from the preceding cycle
This represents a paradigm shift: Rather than relying on historical AMH values, measuring AMH in the early follicular phase of the specific cycle you're evaluating provides superior predictive accuracy 1.
Understanding AMH Variability
Inter-Cycle Variability (Between Cycles)
AMH exhibits significant fluctuation between consecutive menstrual cycles 1:
- Median cycle-to-cycle variation: 44.3%
- Normal responders: mean change of 0.60 ± 0.46 ng/ml
- Poor responders: mean change of 0.28 ± 0.28 ng/ml
- Approximately 20% of patients were reclassified between normal and poor responder categories based on second measurements
Intra-Cycle Variability (Within a Single Cycle)
AMH levels vary within a menstrual cycle, though the clinical significance is debated 2, 3, 4:
- Follicular phase AMH is 11.5% higher than luteal phase 2
- This difference is statistically significant but relatively modest
- Strong positive correlations exist between follicular and luteal measurements (r = 0.822-0.899) 3
Midluteal AMH Shows Strongest Predictive Value
Interestingly, one study found midluteal AMH had the highest correlation with oocyte retrieval (r = 0.89), followed closely by day 3 AMH (r = 0.88) 5. However, this finding requires validation and conflicts with the practical recommendation to measure in early follicular phase.
Clinical Algorithm for AMH Timing
For Ovarian Reserve Assessment (General)
- Measure in early follicular phase (days 2-5)
- Acceptable to measure at any cycle phase for general screening, but interpret with awareness of 11.5% variation
- For borderline values near clinical cut-offs, repeat measurement in follicular phase to avoid misclassification 3
For Predicting COS Response (IVF/Fertility Treatment)
- Measure AMH in the early follicular phase of the actual COS cycle being planned 1
- Do not rely solely on AMH values from months or cycles prior
- This approach provides the most accurate prediction of total and mature oocyte yield
For PCOS Diagnosis
- Current international guidelines (2019) identify that AMH measurement timing requires standardization before it can replace ultrasound for PCOS diagnosis 6
- When used, measure in early follicular phase
- AMH is not yet recommended as a standalone diagnostic tool, particularly in adolescents 7
Common Pitfalls to Avoid
Don't Assume AMH is Completely Stable
The traditional teaching that AMH is "cycle-independent" is oversimplified. While more stable than FSH, AMH does fluctuate both within and between cycles 1, 2, 4.
Don't Use Old AMH Values for Current Cycle Predictions
Using AMH from a previous cycle to predict current COS outcomes results in weaker correlations and potential misclassification of 20% of patients 1.
Don't Ignore Values Near Cut-Offs
For patients with AMH levels near clinical decision thresholds (for poor response or hyperstimulation risk), the 11.5% intra-cycle variation and 44.3% inter-cycle variation can change clinical classification 3, 4. Repeat measurement is warranted.
Assay Standardization Matters
Different AMH assays show substantial discrepancies in results 6. Ensure consistent use of the same assay platform when tracking AMH over time, with preference for newer automated platforms like Elecsys-AMH 1.
Special Populations
Adolescents
- AMH should not be used as a standalone diagnostic tool for PCOS in adolescents due to physiological multifollicular ovaries 7
- Optimal timing and cut-offs for adolescents remain undefined
Cancer Survivors
- Insufficient evidence exists for optimal timing and frequency of AMH screening in pediatric cancer survivors 8
- AMH drops acutely during chemotherapy with variable recovery depending on treatment intensity